These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10344729)

  • 1. Decay accelerating factor (CD55): a target for cancer vaccines?
    Spendlove I; Li L; Carmichael J; Durrant LG
    Cancer Res; 1999 May; 59(10):2282-6. PubMed ID: 10344729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization against tumor cell surface complement-regulatory proteins.
    Durrant LG; Spendlove I
    Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions.
    Spendlove L; Li L; Potter V; Christiansen D; Loveland BE; Durrant LG
    Eur J Immunol; 2000 Oct; 30(10):2944-53. PubMed ID: 11069077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
    Ullenhag GJ; Spendlove I; Watson NF; Kallmeyer C; Pritchard-Jones K; Durrant LG
    Clin Immunol; 2008 Aug; 128(2):148-54. PubMed ID: 18508409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
    Ullenhag GJ; Spendlove I; Watson NF; Indar AA; Dube M; Robins RA; Maxwell-Armstrong C; Scholefield JH; Durrant LG
    Clin Cancer Res; 2006 Dec; 12(24):7389-96. PubMed ID: 17121873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD55 is over-expressed in the tumour environment.
    Li L; Spendlove I; Morgan J; Durrant LG
    Br J Cancer; 2001 Jan; 84(1):80-6. PubMed ID: 11139317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.
    Chen S; Caragine T; Cheung NK; Tomlinson S
    Cancer Res; 2000 Jun; 60(11):3013-8. PubMed ID: 10850450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular cloning and characterization of novel splicing variants of human decay-accelerating factor.
    Osuka F; Endo Y; Higuchi M; Suzuki H; Shio Y; Fujiu K; Kanno R; Oishi A; Terashima M; Fujita T; Gotoh M
    Genomics; 2006 Sep; 88(3):316-22. PubMed ID: 16503113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decay-accelerating factor (DAF/CD55) is a functional active element of the LPS receptor complex.
    Heine H; Ulmer AJ; El-Samalouti VT; Lentschat A; Hamann L
    J Endotoxin Res; 2001; 7(3):227-31. PubMed ID: 11581575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
    Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F
    Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2.
    Zeytin HE; Tripathi PK; Bhattacharya-Chatterjee M; Foon KA; Chatterjee SK
    Cancer Gene Ther; 2000 Nov; 7(11):1426-36. PubMed ID: 11129285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD55/decay accelerating factor is part of the lipopolysaccharide-induced receptor complex.
    Heine H; El-Samalouti VT; Nötzel C; Pfeiffer A; Lentschat A; Kusumoto S; Schmitz G; Hamann L; Ulmer AJ
    Eur J Immunol; 2003 May; 33(5):1399-408. PubMed ID: 12731067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
    Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
    Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy.
    Bjørge L; Stoiber H; Dierich MP; Meri S
    Scand J Immunol; 2006 May; 63(5):355-64. PubMed ID: 16640659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 37 kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers.
    Coggin JH; Barsoum AL; Rohrer JW
    Anticancer Res; 1999; 19(6C):5535-42. PubMed ID: 10697612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-surface expression of complement restriction factors and sialyl Lewis antigens in oral carcinoma: relevance to chemo-immunotherapy.
    Ravindranath NM; Nishimoto K; Chu K; Shuler C
    Anticancer Res; 2000; 20(1A):21-6. PubMed ID: 10769630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
    Clayton A; Harris CL; Court J; Mason MD; Morgan BP
    Eur J Immunol; 2003 Feb; 33(2):522-31. PubMed ID: 12645951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-1-HSA (CD80-CD24), a recombinant hybrid costimulatory molecule retains ligand binding and costimulatory functions.
    Wang YC; Sashidharamurthy R; Nagarajan S; Selvaraj P
    Immunol Lett; 2006 Jun; 105(2):185-92. PubMed ID: 16621031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A monoclonal antibody that blocks the complement regulatory activity of guinea pig erythrocytes and characterization of the antigen involved as guinea pig decay-accelerating factor.
    Okada N; Tanaka H; Takizawa H; Okada H
    J Immunol; 1995 Jun; 154(11):6103-11. PubMed ID: 7538542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.